KIT and gastrointestinal stromal tumor: The identification of activating mutations in the v-kit Hardy-Zuckerman feline sarcoma viral oncogene homolog (KIT) or platelet-derived growth factor receptor alpha (PDGFRA) tyrosine kinases in ~85% of gastrointestinal stromal tumors (GISTs) enabled the introduction of targeted therapies that have proven much more effective than traditional chemotherapy in the treatment of advanced disease (reviewed in [1]).